Tag
This study explores how physical activity influences lung and kidney function in COVID-19 survivors, showing active survivors had better lung outcomes but no significant kidney benefits, highlighting the importance of tailored rehabilitatio
This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressi
This study reveals that liver transplant recipients exhibit significantly reduced lung function and increased dyspnea compared to the general population, highlighting the need for heightened pulmonary surveillance in this vulnerable group.
Combined analysis of the TETON-1 and TETON-2 trials confirms inhaled treprostinil significantly slows lung function decline, reduces clinical worsening and exacerbations, and improves quality of life in idiopathic pulmonary fibrosis over on
This analysis of U.S. CF Foundation registry data reveals that inhaled antibiotics confer lung function benefits primarily in chronic Pseudomonas aeruginosa infections, but their treatment benefit has declined with CFTR modulator use. Risks
Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilati
Deupirfenidone, a deuterated form of pirfenidone, demonstrated efficacy in slowing lung function decline in IPF patients, with a favorable safety profile in a phase 2b trial, offering promise for improved treatment outcomes.
This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain
Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p
A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.
This review synthesizes trial evidence showing that nicotine-containing e-cigarettes modestly improve lipid profiles but cause no significant changes in lung function or other cardiovascular markers compared to cigarette substitutes in smok
